Immunocore Publishes Presentation on Phase 1 Brenetafusp Study in Metastatic Uveal Melanoma

By Public Technologies
  • Immunocore published a Phase 1 presentation evaluating brenetafusp alone or with tebentafusp in metastatic uveal melanoma.
  • The first-line combination cohort of 17 patients achieved a 29% response rate; median progression-free survival was 8.1 months.
  • Two-year overall survival reached 70%, with median survival follow-up of 29 months.
  • Combination treatment showed no new safety signals; no treatment-related adverse events caused discontinuation or death across either treatment group.
  • The findings support further evaluation in DUET-UVEAL, a randomized Phase 2/3 study in planning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.